The year's new drugs & biologics 2015 - part II:Trends and highlights that marked a complicated year.
This eagle's-eye overview of the drug industry in 2015 provides insight into some of last year's top stories, including drug pricing, orphan drug development, the FDA's priority review voucher system, pipeline attrition, and the ongoing movement in M&A. We also take a look into the crystal ball and anticipate the new drugs that may reach the market in 2016.
Thomson Reuters, Barcelona, Spain. ann.graul@thomsonreuters.com.
A I
AI
Graul
Thomson Reuters, Barcelona, Spain.
E
E
Cruces
Thomson Reuters, Barcelona, Spain.
C
C
Dulsat
Thomson Reuters, Barcelona, Spain.
M
M
Tracy
D001688:Biological Products; D017277:Drug Approval; D016527:Drug Costs; D055808:Drug Discovery; D006801:Humans; D009965:Orphan Drug Production; D004364:Pharmaceutical Preparations; D014481:United States; D014486:United States Food and Drug Administration
D001688:Biological Products; D004364:Pharmaceutical Preparations
Discontinuations; Drug pricing; FDA; Orphan drug; Priority review; Voucher